Skip to main content
. Author manuscript; available in PMC: 2019 Nov 11.
Published in final edited form as: Adv Drug Deliv Rev. 2018 Jul 21;130:113–130. doi: 10.1016/j.addr.2018.07.009

Figure 5.

Figure 5.

(A) Release process of exenatide from microspheres. (B) Mean concentration-time profile of exenatide following single dose of Bydureon®. (C) Mean concentration-time profile of exenatide following repeated weekly administrations of Bydureon® (exenatide ER same as exenatide QW) compared with a single administration of Byetta® (exenatide IR). Adapted with permission of © 2011 Adis Data Information BV from Fineman et al. Clin Pharmacokinet 2011; 50 (1).[97]